Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Anthony T.�C. Chan(Chinese University of Hong Kong), Alex Y. Chang(Cornell University), Edwin P. Hui(Johns Hopkins University), Boon Cher Goh(National University of Singapore), Ka‐Fai To(Chinese University of Hong Kong), M. Mueser(Chinese University of Hong Kong), Xiao Lin(Chinese University of Hong Kong), Nadia Amellal(Merck KGaA, Darmstadt (Germany)), Ruey‐Long Hong(National Taiwan University), Brigette Ma(Chinese University of Hong Kong), Mow-Ming Hsu(National Taiwan University Hospital), Jacqueline Whang‐Peng(Taipei Medical University), Michael Millward(University of Western Australia), Tsang‐Wu Liu(National Health Research Institutes)
Journal of Clinical Oncology
April 5, 2005
10.1200/jco.2005.02.147
Cited by 292

Related Papers

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
|The Lancet|2005|2.1k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
|Journal of Clinical Oncology|2003|943
Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2006|705